SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)
Close on Nov 18, 2026Market cap $291.16MP/E –Yield –
SAB Biotherapeutics cash
Cash and short-term investments held at the end of each period.
SAB Biotherapeutics's cash was $102.63M at Jun 30, 2026. For fiscal 2025 it was $96.59M, up 365.3% from the year before. The highest annual figure on record is $96.59M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.59M | +365.3% |
| FY2024 | Dec 31, 2024 | $20.76M | -63.3% |
| FY2023 | Dec 31, 2023 | $56.57M | +275.9% |
| FY2022 | Dec 31, 2022 | $15.05M | -61.9% |
| FY2021 | Dec 31, 2021 | $39.55M | +213.6% |
| FY2020 | Dec 31, 2020 | $12.61M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $102.63M | +1696.3% |
| Q1 FY2026 | Mar 31, 2026 | $107.39M | +735.7% |
| Q4 FY2025 | Dec 31, 2025 | $96.59M | +365.3% |
| Q3 FY2025 | Sep 30, 2025 | $110.88M | +264.7% |
| Q2 FY2025 | Jun 30, 2025 | $5.71M | -84.7% |
| Q1 FY2025 | Mar 31, 2025 | $12.85M | -70.8% |
| Q4 FY2024 | Dec 31, 2024 | $20.76M | -63.3% |
| Q3 FY2024 | Sep 30, 2024 | $30.40M | +1153.4% |
| Q2 FY2024 | Jun 30, 2024 | $37.33M | +380.1% |
| Q1 FY2024 | Mar 31, 2024 | $44.06M | +237.3% |
| Q4 FY2023 | Dec 31, 2023 | $56.57M | +275.9% |
| Q3 FY2023 | Sep 30, 2023 | $2.43M | -70.9% |
| Q2 FY2023 | Jun 30, 2023 | $7.77M | -53.2% |
| Q1 FY2023 | Mar 31, 2023 | $13.06M | -41.7% |
| Q4 FY2022 | Dec 31, 2022 | $15.05M | -61.9% |
| Q3 FY2022 | Sep 30, 2022 | $8.33M | -22.5% |
| Q2 FY2022 | Jun 30, 2022 | $16.62M | +62.4% |
| Q1 FY2022 | Mar 31, 2022 | $22.41M | +11.3% |
| Q4 FY2021 | Dec 31, 2021 | $39.55M | +213.6% |
| Q3 FY2021 | Sep 30, 2021 | $10.75M | – |
| Q2 FY2021 | Jun 30, 2021 | $10.23M | – |
| Q1 FY2021 | Mar 31, 2021 | $20.13M | – |
| Q4 FY2020 | Dec 31, 2020 | $12.61M | – |
See a number that looks wrong?